Published in J Digit Imaging on November 13, 2007
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Recent advances in standards for Collaborative Digital Anatomic Pathology. Diagn Pathol (2011) 1.18
How to measure image quality in tissue-based diagnosis (diagnostic surgical pathology). Diagn Pathol (2008) 1.14
Epigenetically altered miR-193b targets cyclin D1 in prostate cancer. Cancer Med (2015) 0.92
JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format. Virchows Arch (2010) 0.90
Evaluation and optimization for liquid-based preparation cytology in whole slide imaging. J Pathol Inform (2011) 0.89
Serendipia: Castilla-La Mancha telepathology network. Diagn Pathol (2008) 0.85
Overall and worst gleason scores are equally good predictors of prostate cancer progression. BMC Urol (2011) 0.84
A survey on non specialized off-the-shelf JPEG2000 viewers for digital microscopy use. Diagn Pathol (2008) 0.84
The proprotein convertase subtilisin/kexin furinA regulates zebrafish host response against Mycobacterium marinum. Infect Immun (2015) 0.78
Technical Challenges of Enterprise Imaging: HIMSS-SIIM Collaborative White Paper. J Digit Imaging (2016) 0.75
[Pathowiki. A free expert database for pathology]. Pathologe (2012) 0.75
Critical comparison of 31 commercially available digital slide systems in pathology. Int J Surg Pathol (2006) 7.06
Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol (2005) 2.56
A digital atlas of breast histopathology: an application of web based virtual microscopy. J Clin Pathol (2004) 2.40
Innovations in medical imaging and virtual microscopy. Hum Pathol (2005) 1.35
Integrating histology and histopathology teaching in practical classes using virtual slides. Anat Rec B New Anat (2006) 1.32
Virtual microscopy. J Clin Pathol (2004) 1.24
A randomized controlled trial of the diagnostic accuracy of internet-based telepathology compared with conventional microscopy. Histopathology (2007) 1.23
The use of digital 'virtual slides' in the quality assessment of haematological morphology: results of a pilot exercise involving UK NEQAS(H) participants. Br J Haematol (2005) 1.18
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA (2004) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol (2009) 3.63
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol (2005) 2.56
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res (2003) 2.15
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 1.70
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther (2007) 1.70
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res (2002) 1.53
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol (2005) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett (2010) 1.35
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry. Histopathology (2012) 1.30
Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res (2003) 1.27
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol (2012) 1.20
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett (2011) 1.18
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat (2007) 1.14
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest (2003) 1.10
Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance. PLoS Negl Trop Dis (2008) 1.08
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol (2004) 1.08
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol (2011) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep (2010) 1.05
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer (2003) 1.04
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer (2007) 1.04
The calcium-binding protein S100P in normal and malignant human tissues. BMC Clin Pathol (2008) 1.02
Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors. Mod Pathol (2010) 1.01
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet (2007) 0.98
Cancer incidence in families with multiple glioma patients. Int J Cancer (2002) 0.98
Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res (2005) 0.97
Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression. J Neurooncol (2006) 0.96
Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. Cancer Genet Cytogenet (2006) 0.92
Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives. J Clin Pathol (2013) 0.91
Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res (2011) 0.91
Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett (2007) 0.90
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol (2009) 0.90
Chemical castration and anti-androgens induce differential gene expression in prostate cancer. J Pathol (2012) 0.89
Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. Cancer Lett (2005) 0.88
Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. Eur J Cancer (2006) 0.88
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer (2012) 0.87
HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005. Breast Cancer Res (2009) 0.86
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma. BMC Cancer (2009) 0.85
A novel biodegradable biliary stent in the normal duct hepaticojejunal anastomosis: an 18-month follow-up in a large animal model. J Gastrointest Surg (2007) 0.85
Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing. Breast Cancer Res Treat (2002) 0.83
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2009) 0.83
Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol (2014) 0.83
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol (2009) 0.82
Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer (2009) 0.81
Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer. Genes Chromosomes Cancer (2012) 0.81
Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. J Otolaryngol Head Neck Surg (2010) 0.80
Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas. Mod Pathol (2005) 0.80
Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours. Scand J Gastroenterol (2006) 0.79
Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Int J Gynecol Pathol (2014) 0.79
Evaluation of a web-based system for survival estimation in breast cancer. Stud Health Technol Inform (2003) 0.78
The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. Int J Clin Exp Pathol (2013) 0.78
Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. Int J Oncol (2002) 0.78
Glucocorticoid receptor-mediated transcriptional activation of S100P gene coding for cancer-related calcium-binding protein. J Cell Biochem (2011) 0.78
Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. Cancer Genet Cytogenet (2003) 0.76
Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. Gynecol Oncol (2004) 0.76
Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes Cancer (2015) 0.76
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteins. PLoS One (2011) 0.76
Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation. Genes Chromosomes Cancer (2002) 0.76
L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. Int J Gynecol Cancer (2016) 0.75
The role of insulin-like growth factor-I receptor in the development of Herceptin resistance. Mol Cancer Ther (2005) 0.75
Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. Hum Pathol (2011) 0.75
Ultra thin needle histology may have impact in diagnosing chronic pancreatitis. Scand J Gastroenterol (2007) 0.75
Analyzing toposimerase II-alpha and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer. Acta Oncol (2009) 0.75